Ensituximab

Modify Date: 2024-02-03 17:37:04

Ensituximab structure	Common Name	Ensituximab
	CAS Number	1092658-06-4	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Ensituximab

Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer[1][2].

Name	Ensituximab

Description	Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others
In Vitro	Ensituximab (NPC-1C) 是一种嵌合 IgG1 单克隆抗体，在结合其靶标后促进抗体依赖性细胞的细胞毒性，MUC5AC 是一种肿瘤特异性变体，一种由结直肠癌 (CRC) 和胰腺癌特异性表达的抗原[1]。
References	[1]. Richard D Kim, et al. Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer. Clin Cancer Res. 2020 Jul 15;26(14):3557-3564. [2]. Julian A Marin-Acevedo, et al. Cancer immunotherapy beyond immune checkpoint inhibitors. J Hematol Oncol. 2018 Jan 12;11(1):8.

No Any Chemical & Physical Properties

Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Ensituximab (anti-MUC5AC)
Price: Click To Check
Purity: 95.0%
Delivery: 10 Day
Contact: Yang
Email: sales@echemcloud.com

Get all suppliers and price by the below link:

Ensituximab suppliers

Ensituximab price